Neos Therapeutics (NASDAQ: NEOS) is one of 112 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Neos Therapeutics to similar businesses based on the strength of its dividends, analyst recommendations, risk, profitability, earnings, institutional ownership and valuation.
Volatility and Risk
Neos Therapeutics has a beta of -0.9, suggesting that its share price is 190% less volatile than the S&P 500. Comparatively, Neos Therapeutics’ competitors have a beta of 0.86, suggesting that their average share price is 14% less volatile than the S&P 500.
This is a breakdown of recent ratings and price targets for Neos Therapeutics and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Neos Therapeutics Competitors||943||3783||5998||164||2.49|
Neos Therapeutics presently has a consensus price target of $16.75, indicating a potential upside of 92.53%. As a group, “Pharmaceuticals” companies have a potential upside of 26.68%. Given Neos Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Neos Therapeutics is more favorable than its competitors.
This table compares Neos Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Neos Therapeutics Competitors||-3,613.33%||-52.24%||-8.27%|
Institutional & Insider Ownership
44.3% of Neos Therapeutics shares are owned by institutional investors. Comparatively, 44.2% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 5.2% of Neos Therapeutics shares are owned by insiders. Comparatively, 12.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Neos Therapeutics and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Neos Therapeutics||$15.62 million||-$69.70 million||-1.96|
|Neos Therapeutics Competitors||$7.86 billion||$2.50 billion||1.27|
Neos Therapeutics’ competitors have higher revenue and earnings than Neos Therapeutics. Neos Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Neos Therapeutics competitors beat Neos Therapeutics on 7 of the 12 factors compared.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.